Study in mice advances combination immune therapy for ovarian cancer

(Johns Hopkins Medicine) Delivering two federally approved immunity-altering drugs together significantly extended the lives of mice injected with human ovarian cancer cells, an early proof-of-concept experiment that may advance treatment for the most deadly -- although rare -- gynecologic malignancy in humans, according to scientists at the Johns Hopkins Kimmel Cancer Center who performed the research.